Expert Interview
Discussing Corcept Therapeutics Phase 3 ROSELLA study of Relacorilant + Nab-pac in Platinum Resistant Ovarian Cancer (PROC)
Ticker(s): CORTInstitution: Kaiser Permanente
- Gynecologic Medical Oncologist at KP.
- Manages over 55 patients with ovarian cancer.
- Clinical and Research interest in advanced ovarian research trials.
If you had to rate your level of excitement on a 1 to 10 scale for the potential of relacorilant plus nab-paclitaxelpivotal, what would it be and why?
Added By: wilson_adminPlease describe your clinical practice. How many patients with ovarian cancer? What percent of ovarian cancers become platinum-resistant and how do you measure benefit when proceeding with treatment?
Added By: wilson_adminCould you please tell us more about the mechanisms of platinum resistance, and the treatment options patients with PROC have? And what is platinum refractory disease?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
